Book An Appointment

Tirzepatide vs Semaglutide for Weight Loss

Feature Mounjaro (Tirzepatide) Ozempic (Semaglutide)
Manufacturer
Eli Lilly & Company
Novo Nordisk
Drug class
Dual GIP/GLP-1 receptor agonist
GLP-1 receptor agonist
FDA use
Type 2 diabetes
Type 2 diabetes
Off-label use
Weight loss (formally approved as Zepbound)
Weight loss (approved as Wegovy for obesity)
Administration
Weekly injection
Weekly injection

Mounjaro vs Ozempic — How They Compare for Weight Loss

When exploring medical weight-loss options, two injectable medications have stood out in recent years: Mounjaro (tirzepatide) and Ozempic (semaglutide). Originally developed to manage type 2 diabetes, both have shown meaningful effects on appetite suppression and weight reduction — making them highly searched treatments in Singapore and globally.

Mechanism of Action — What Makes Them Different

  • Ozempic (semaglutide) – Acts on the GLP-1 pathway, mimicking a gut hormone that slows gastric emptying, increases satiety, and helps moderate weight loss.
  • Mounjaro (tirzepatide) – A dual-action medication that activates both GLP-1 and GIP pathways, enhancing insulin response, suppressing appetite, and leading to greater weight reduction in trials.

This dual hormone action is a key reason why Mounjaro often demonstrates higher efficacy in weight loss outcomes.

Weight Loss Results — Clinical Evidence

Across multiple comparative studies and trials:

  • Mounjaro consistently leads to more weight loss than Ozempic. In head-to-head trials, patients on tirzepatide experienced significantly greater body-weight reduction than those on semaglutide.
  • Some research shows results like ~21% average body weight loss with Mounjaro vs ~11% with Ozempic at comparable treatment durations.

These findings reflect typical clinical outcomes, though real-world results may vary based on individual biology, dosage, lifestyle changes, and treatment duration.

SURPASS-2-trial-Semaglutide-versus-tirzepatide-for-diabetes-Hba1c-and-fasting-glucose-levels
SURPASS-2-trial-Tirzepatide-versus-Semaglutide-for-weight-loss-in-diabetic-patients-weight-loss-in-kg-and-by-percentage-of-body-weight-lipid-levels
SURPASS-2-Trial-Tirzepatide-Mounjaro-versus-Semaglutide-Ozempic-for-diabetes

Side Effects — Similar but Not Identical

Both medications share common gastrointestinal side effects, such as nausea, vomiting, bloating and diarrhoea — especially early during treatment as the body adjusts.

  • Ozempic may have a slightly higher incidence of nausea in some reports.
  • Mounjaro has similar GI profiles but can cause variable patterns of diarrhoea or discomfort depending on dose and individual tolerance.

Any injectable treatment should be initiated and monitored under medical supervision to manage side effects safely.

Practical Considerations

Approved Uses
  • Ozempic is primarily approved for type 2 diabetes, with many clinicians in Singapore prescribing it off-label for weight loss.
  • Mounjaro also treats diabetes, and its close analogue with the same active ingredient branded for weight loss (e.g., Zepbound) shows promising results.
Dosage & Administration
  • Both are once-weekly injections, but the dose ranges and titration schedules differ, with Mounjaro offering a broader range for more aggressive weight-loss targets.
Availability in Singapore
  • At present, Ozempic is more widely accessible locally, while supply and approval pathways for Mounjaro for purely weight-loss indications are evolving. Speak to a licensed clinician in Singapore to understand current availability and suitability.

Choosing Between Them — What Matters Most

Your choice depends on goals, health profile and clinician guidance
  • Choose Ozempic if you’re looking for a treatment with an established safety profile and moderate weight loss as part of metabolic care.
  • Mounjaro may be more suitable if your priority is maximising weight loss under strict medical oversight.

Always consult a doctor to tailor dosing, review contraindications, and support adherence.

Summary Table — Quick Comparison

Feature Mounjaro (Tirzepatide) Ozempic (Semaglutide)
Hormone Target
Dual (GLP-1 + GIP)
Single (GLP-1)
Weight Loss Efficacy
Higher (~20%+)
Moderate (~10–15%)
Side Effect Profile
Similar GI effects
Similar GI effects
Approved for Diabetes
Yes
Yes
Approved for Weight Loss
Off-label / evolving
Off-label (Wegovy is the semaglutide weight-loss branded option)

Contact Us

Book An Appointment Now

Take the first step toward a healthier, more confident you. Our medical team is ready to answer your questions and guide you through safe, personalised weight-loss options. Reach out today to schedule a consultation or speak with our care specialists.